Search for: "K. Doe" Results 441 - 460 of 13,825
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
26 Oct 2023, 9:01 pm by renholding
  This does not necessarily mean that the SEC staff has cast doubt on the availability of a particular exemption in the context of a bail-in – only that it is incumbent on the issuer of the securities, with the assistance of its counsel, to determine whether an exemption is available. [read post]
25 Oct 2023, 9:01 pm by renholding
It does not blame regulatory tailoring for reduced supervisory intensity, except when SVB had assets between $50-$100 billion. [read post]
25 Oct 2023, 9:24 am by Silverberg Zalantis LLC
K-Tooling https://www.nycourts.gov/reporter/3dseries/2023/2023_05349.htm the Court found, omitting the owner of the property at issue from the initial petition in the Article 78 challenge to the use variance could be cured through the relation back doctrine in CPLR 203 (C). [read post]
25 Oct 2023, 6:07 am
Ineligibility of the U.S. citizen petitioner - If the U.S. citizen sponsor does not meet the legal requirements to petition for a K-1 visa, the visa may be denied. [read post]
25 Oct 2023, 6:07 am
Ineligibility of the U.S. citizen petitioner - If the U.S. citizen sponsor does not meet the legal requirements to petition for a K-1 visa, the visa may be denied. [read post]
25 Oct 2023, 4:20 am by David Lynn
Companies that grant options should revisit policies regarding the timing of option grants, or consider adopting a policy if the company does not have one, in light of the new disclosure requirements regarding option grants adopted as part of the Rule 10b5-1 and insider trading disclosure rulemaking (see the January-February 2023 issue of The Corporate Counsel). 5. [read post]
25 Oct 2023, 3:17 am by jonathanturley
During the interview, Stavast’s questions were drowned out by loud-and-clear chants of “F—k Joe Biden. [read post]
24 Oct 2023, 3:20 am by Kurt R. Karst
  Unlike 510(k)s, using eSTAR for De Novos does not eliminate the acceptance review process, which must be conducted and completed within 15 calendar days of FDA receiving a De Novo request. [read post]
23 Oct 2023, 4:10 am by David Lynn
Also, as I noted in the blog at the end of last month, the Staff issued nine new Regulation S-K Compliance and Disclosure Interpretations and updated one existing Regulation S-K Compliance and Disclosure Interpretation to provide guidance regarding the pay versus performance disclosure requirements. [read post]
22 Oct 2023, 9:01 pm by renholding
Among other things, Item 303 of SEC Regulation S-K requires issuers to disclose “any known trends or uncertainties that have had or that are reasonably likely to have a material favorable or unfavorable impact” on its financial performance.[6] Item 303 does not explicitly provide a private right of action for investors to sue if these disclosure requirements are not met—it only serves as the basis for an SEC enforcement action. [read post]
18 Oct 2023, 4:29 am by jonathanturley
“This is what Israel does to the Palestinians,” Greenberg reportedly said, “How many people died in the Holocaust? [read post]
18 Oct 2023, 3:30 am by John Jenkins
This K&L Gates memo looks at the terms of recent settlements and identifies some of the cooperation factors that are likely to contribute to reduced penalties – or even a decision not to impose penalties. [read post]
18 Oct 2023, 2:41 am by Kurt R. Karst
Although there is some discussion in the examples that relates to whether the predicate device required clinical data for 510(k) clearance, we found that the Draft Guidance does not explicitly address the question of whether or not inclusion of clinical data in the predicate device 510(k) provides any bearing on whether clinical data will be needed for a new device. [read post]
17 Oct 2023, 9:48 pm by Cari Rincker
TOD applies to an investment account, such as an individual retirement account, 401(k), brokerage account, and other accounts holding securities. [read post]